You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAldesleukin
Accession NumberDB00041  (BTD00082, BIOD00082)
TypeBiotech
GroupsApproved
DescriptionAldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
Protein structureDb00041
Related Articles
Protein chemical formulaC690H1115N177O202S6
Protein average weight15314.8 Da
Sequences
>Aldesleukin sequence
MAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCL
EEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLN
RWITFCQSIISTLT
Download FASTA Format
Synonyms
125-L-serine-2-133-interleukin 2 (human reduced)
Interleukin-2 aldesleukin
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ProleukinInjection1.1 mg/mLIntravenousNovartis Pharmaceuticals Corporation1992-05-06Not applicableUs
ProleukinInjection, powder, lyophilized, for solution1.1 mg/mLIntravenousPrometheus Laboratories Inc.1992-05-05Not applicableUs
ProleukinPowder, for solution22000000 unitIntravenousNovartis Pharmaceuticals Canada Inc1995-12-31Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIM89N0Q7EQR
CAS number110942-02-4
Pharmacology
IndicationFor treatment of adults with metastatic renal cell carcinoma.
Structured Indications
PharmacodynamicsUsed to treat renal cell carcinoma, Aldesleukin induces the enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines, the enhancement of lymphocyte cytotoxicity, the induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and the induction of interferon-gamma production. IL-2 is normally produced by the body, secreted by T cells, and stimulates growth and differentiation of T cell response. It can be used in immunotherapy to treat cancer. It enhances the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor.
Mechanism of actionAldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells.
TargetKindPharmacological actionActionsOrganismUniProt ID
Interleukin-2 receptor subunit betaProteinyes
agonist
modulator
HumanP14784 details
Interleukin-2 receptor subunit alphaProteinyes
agonist
modulator
HumanP01589 details
Cytokine receptor common subunit gammaProteinyes
agonist
HumanP31785 details
Related Articles
AbsorptionNot Available
Volume of distribution

0.18 l/kg

Protein bindingNot Available
MetabolismNot Available
Route of eliminationThe pharmacokinetic profile of Proleukin is characterized by high plasma concentrations following a short IV infusion, rapid distribution into the extravascular space and elimination from the body by metabolism in the kidneys with little or no bioactive protein excreted in the urine. Following the initial rapid organ distribution, the primary route of clearance of circulating proleukin is the kidney. Greater than 80% of the amount of Proleukin distributed to plasma, cleared from the circulation and presented to the kidney is metabolized to amino acids in the cells lining the proximal convoluted tubules.
Half life13 min-85 min
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may decrease the antineoplastic activities of Aldesleukin.Investigational
19-norandrostenedione19-norandrostenedione may decrease the antineoplastic activities of Aldesleukin.Experimental, Illicit
4-Androstenedione4-Androstenedione may decrease the antineoplastic activities of Aldesleukin.Experimental, Illicit
5-androstenedione5-androstenedione may decrease the antineoplastic activities of Aldesleukin.Experimental, Illicit
AcebutololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Acebutolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Acetazolamide.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Aldesleukin.Approved
AlclometasoneAlclometasone may decrease the antineoplastic activities of Aldesleukin.Approved
AldosteroneAldosterone may decrease the antineoplastic activities of Aldesleukin.Experimental
AliskirenThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Aliskiren.Approved, Investigational
AmcinonideAmcinonide may decrease the antineoplastic activities of Aldesleukin.Approved
AmifostineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Aldesleukin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amyl Nitrite.Approved
AnecortaveAnecortave may decrease the antineoplastic activities of Aldesleukin.Investigational
AnvirzelAnvirzel may decrease the cardiotoxic activities of Aldesleukin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Aldesleukin.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Atenolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Azilsartan medoxomil.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Aldesleukin.Experimental
BarbitalBarbital may increase the hypotensive activities of Aldesleukin.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Barnidipine.Approved
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Aldesleukin.Investigational
BeclomethasoneBeclomethasone may decrease the antineoplastic activities of Aldesleukin.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may decrease the antineoplastic activities of Aldesleukin.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bendroflumethiazide.Approved
BepridilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may decrease the antineoplastic activities of Aldesleukin.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Aldesleukin.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Brimonidine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bromocriptine.Approved, Investigational
BudesonideBudesonide may decrease the antineoplastic activities of Aldesleukin.Approved
BumetanideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bupivacaine.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aldesleukin.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Candesartan.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Carbetocin.Approved
CarteololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Carvedilol.Approved, Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorthalidone.Approved
CiclesonideCiclesonide may decrease the antineoplastic activities of Aldesleukin.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Cilnidipine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clevidipine.Approved
ClobetasolClobetasol may decrease the antineoplastic activities of Aldesleukin.Investigational
Clobetasol propionateClobetasol propionate may decrease the antineoplastic activities of Aldesleukin.Approved
ClocortoloneClocortolone may decrease the antineoplastic activities of Aldesleukin.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clonidine.Approved
ClozapineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Conivaptan.Approved, Investigational
Cortisone acetateCortisone acetate may decrease the antineoplastic activities of Aldesleukin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Aldesleukin.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dapagliflozin.Approved
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may decrease the antineoplastic activities of Aldesleukin.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Desflurane.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Aldesleukin.Approved
DesoximetasoneDesoximetasone may decrease the antineoplastic activities of Aldesleukin.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may decrease the antineoplastic activities of Aldesleukin.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may decrease the antineoplastic activities of Aldesleukin.Experimental, Vet Approved
DexamethasoneDexamethasone may decrease the antineoplastic activities of Aldesleukin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may decrease the antineoplastic activities of Aldesleukin.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexmedetomidine.Approved, Vet Approved
DiatrizoateThe risk of a hypersensitivity reaction to Diatrizoate is increased when it is combined with Aldesleukin.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Diclofenamide.Approved
DiflorasoneDiflorasone may decrease the antineoplastic activities of Aldesleukin.Approved
DifluocortoloneDifluocortolone may decrease the antineoplastic activities of Aldesleukin.Approved
DifluprednateDifluprednate may decrease the antineoplastic activities of Aldesleukin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Aldesleukin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Aldesleukin.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aldesleukin.Approved, Investigational
DoxazosinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Doxazosin.Approved
DuloxetineAldesleukin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Enalaprilat.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Eprosartan.Approved
EquileninEquilenin may decrease the antineoplastic activities of Aldesleukin.Experimental
EquilinEquilin may decrease the antineoplastic activities of Aldesleukin.Approved
EsmololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Esmolol.Approved
EstroneEstrone may decrease the antineoplastic activities of Aldesleukin.Approved
Estrone sulfateEstrone sulfate may decrease the antineoplastic activities of Aldesleukin.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Etacrynic acid.Approved
Ethiodized oilThe risk of a hypersensitivity reaction to Ethiodized oil is increased when it is combined with Aldesleukin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Fenoldopam.Approved
FimasartanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Fimasartan.Approved
fluasteronefluasterone may decrease the antineoplastic activities of Aldesleukin.Investigational
FludrocortisoneFludrocortisone may decrease the antineoplastic activities of Aldesleukin.Approved
FlumethasoneFlumethasone may decrease the antineoplastic activities of Aldesleukin.Approved, Vet Approved
FlunisolideFlunisolide may decrease the antineoplastic activities of Aldesleukin.Approved, Investigational
Fluocinolone AcetonideFluocinolone Acetonide may decrease the antineoplastic activities of Aldesleukin.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may decrease the antineoplastic activities of Aldesleukin.Approved, Investigational
FluocortoloneFluocortolone may decrease the antineoplastic activities of Aldesleukin.Approved, Withdrawn
FluorometholoneFluorometholone may decrease the antineoplastic activities of Aldesleukin.Approved
FluprednideneFluprednidene may decrease the antineoplastic activities of Aldesleukin.Approved, Withdrawn
FluprednisoloneFluprednisolone may decrease the antineoplastic activities of Aldesleukin.Approved
FlurandrenolideFlurandrenolide may decrease the antineoplastic activities of Aldesleukin.Approved
Fluticasone furoateFluticasone furoate may decrease the antineoplastic activities of Aldesleukin.Approved
Fluticasone PropionateFluticasone Propionate may decrease the antineoplastic activities of Aldesleukin.Approved
FormestaneFormestane may decrease the antineoplastic activities of Aldesleukin.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Fosinopril.Approved
FurosemideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Furosemide.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Halothane.Approved, Vet Approved
HE3286HE3286 may decrease the antineoplastic activities of Aldesleukin.Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Aldesleukin.Approved
HydralazineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneHydrocortisone may decrease the antineoplastic activities of Aldesleukin.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydroflumethiazide.Approved
IloprostThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Indapamide.Approved
IndoraminThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Indoramin.Withdrawn
Interferon Alfa-2a, RecombinantThe risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Aldesleukin.Approved
Interferon Alfa-2b, RecombinantThe risk or severity of adverse effects can be increased when Interferon Alfa-2b, Recombinant is combined with Aldesleukin.Approved
Interferon alfa-n3The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Aldesleukin.Approved, Investigational
Interferon alfacon-1The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Aldesleukin.Approved
IodipamideThe risk of a hypersensitivity reaction to Iodipamide is increased when it is combined with Aldesleukin.Approved
IodixanolThe risk of a hypersensitivity reaction to Iodixanol is increased when it is combined with Aldesleukin.Approved
IohexolThe risk of a hypersensitivity reaction to Iohexol is increased when it is combined with Aldesleukin.Approved
IopamidolThe risk of a hypersensitivity reaction to Iopamidol is increased when it is combined with Aldesleukin.Approved
IopromideThe risk of a hypersensitivity reaction to Iopromide is increased when it is combined with Aldesleukin.Approved
IoversolThe risk of a hypersensitivity reaction to Ioversol is increased when it is combined with Aldesleukin.Approved
IoxilanThe risk of a hypersensitivity reaction to Ioxilan is increased when it is combined with Aldesleukin.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isradipine.Approved
IstaroximeIstaroxime may decrease the antineoplastic activities of Aldesleukin.Investigational
LabetalolThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Lacidipine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Levobupivacaine.Approved
LevodopaAldesleukin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Lisinopril.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Lofexidine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Losartan.Approved
MannitolThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Mannitol.Approved, Investigational
ME-609ME-609 may decrease the antineoplastic activities of Aldesleukin.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Mecamylamine.Approved
MedrysoneMedrysone may decrease the antineoplastic activities of Aldesleukin.Approved
MelengestrolMelengestrol may decrease the antineoplastic activities of Aldesleukin.Vet Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Aldesleukin.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Aldesleukin.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Aldesleukin.Approved
MethylprednisoloneMethylprednisolone may decrease the antineoplastic activities of Aldesleukin.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Metoprolol.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Minoxidil.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Moexipril.Approved
MometasoneMometasone may decrease the antineoplastic activities of Aldesleukin.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nadolol.Approved
NCX 1022NCX 1022 may decrease the antineoplastic activities of Aldesleukin.Investigational
NebivololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Aldesleukin.Approved
NifedipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nifedipine.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroprusside.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Obinutuzumab.Approved
Oleoyl estroneOleoyl estrone may decrease the antineoplastic activities of Aldesleukin.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Olmesartan.Approved, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Aldesleukin.Approved
OxprenololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aldesleukin.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Papaverine.Approved
ParamethasoneParamethasone may decrease the antineoplastic activities of Aldesleukin.Approved
Peginterferon alfa-2aThe risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Aldesleukin.Approved, Investigational
Peginterferon alfa-2bThe risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldesleukin.Approved
PenbutololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Aldesleukin.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Perindopril.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Phenelzine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Aldesleukin.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Phentolamine.Approved
PindololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Pipamperone.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Pramipexole.Approved, Investigational
PrasteronePrasterone may decrease the antineoplastic activities of Aldesleukin.Approved, Nutraceutical
PrazosinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Prazosin.Approved
PrednicarbatePrednicarbate may decrease the antineoplastic activities of Aldesleukin.Approved
PrednisolonePrednisolone may decrease the antineoplastic activities of Aldesleukin.Approved, Vet Approved
PrednisonePrednisone may decrease the antineoplastic activities of Aldesleukin.Approved, Vet Approved
PregnenolonePregnenolone may decrease the antineoplastic activities of Aldesleukin.Experimental
PrimidonePrimidone may increase the hypotensive activities of Aldesleukin.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Propranolol.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Quinapril.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Reserpine.Approved
RimexoloneRimexolone may decrease the antineoplastic activities of Aldesleukin.Approved
RiociguatThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Riociguat.Approved
RisperidoneAldesleukin may increase the hypotensive activities of Risperidone.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sacubitril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Aldesleukin.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Selegiline.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sevoflurane.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sufentanil.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Telmisartan.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Terazosin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Aldesleukin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Aldesleukin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Thioridazine.Approved
TimololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Timolol.Approved
TixocortolTixocortol may decrease the antineoplastic activities of Aldesleukin.Approved
TizanidineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tizanidine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tolcapone.Approved, Withdrawn
TorasemideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Aldesleukin.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may decrease the antineoplastic activities of Aldesleukin.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Triamterene.Approved
ValsartanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Valsartan.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Verapamil.Approved
Food InteractionsNot Available
References
Synthesis Reference

Hans-Ake Fabricius, Roland Stahn, “Serum-free and mitogen-free T-cell growth factor and process for making same.” U.S. Patent US4464355, issued May, 1971.

US4464355
General ReferencesNot Available
External Links
ATC CodesL03AC01
AHFS Codes
  • 10:00.00
PDB Entries
FDA labelNot Available
MSDSNot Available
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
InjectionIntravenous1.1 mg/mL
Injection, powder, lyophilized, for solutionIntravenous1.1 mg/mL
Powder, for solutionIntravenous22000000 unit
Prices
Unit descriptionCostUnit
Proleukin 22 million unit vial1092.34USD each
Proleukin 22000000 unit Solution Vial976.66USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
hydrophobicity-0.192Not Available
isoelectric point7.31Not Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonistmodulator
General Function:
Interleukin-2 receptor activity
Specific Function:
Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.
Gene Name:
IL2RB
Uniprot ID:
P14784
Molecular Weight:
61116.59 Da
References
  1. Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA: Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2788-93. Epub 2006 Feb 13. [PubMed:16477002 ]
  2. Steppan S, Eckart MR, Bajsarowicz K, Sternberg LR, Greve JM, Cassell DJ: Reduced secondary cytokine induction by BAY 50-4798, a high-affinity receptor-specific interleukin-2 analog. J Interferon Cytokine Res. 2006 Mar;26(3):171-8. [PubMed:16542139 ]
  3. Cornish GH, Sinclair LV, Cantrell DA: Differential regulation of T-cell growth by IL-2 and IL-15. Blood. 2006 Jul 15;108(2):600-8. Epub 2006 Mar 28. [PubMed:16569767 ]
  4. Lee KD, Chen HW, Chen CC, Shih YC, Liu HK, Cheng ML: Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2. Oncol Rep. 2006 May;15(5):1211-6. [PubMed:16596189 ]
  5. Maclennan C, Hutchinson P, Holdsworth S, Bardin PG, Freezer NJ: Airway inflammation in asymptomatic children with episodic wheeze. Pediatr Pulmonol. 2006 Jun;41(6):577-83. [PubMed:16617454 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonistmodulator
General Function:
Interleukin-2 receptor activity
Specific Function:
Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T cells.
Gene Name:
IL2RA
Uniprot ID:
P01589
Molecular Weight:
30818.915 Da
References
  1. Waldmann TA: Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol. 2007 Jan;27(1):1-18. Epub 2007 Jan 11. [PubMed:17216565 ]
  2. Recchia F, Cesta A, Rea S: Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy. J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):135-43. [PubMed:16767920 ]
  3. Waldmann TA: Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene. 2007 May 28;26(25):3699-703. [PubMed:17530023 ]
  4. Vlad G, Ho EK, Vasilescu ER, Fan J, Liu Z, Cai JW, Jin Z, Burke E, Deng M, Cadeiras M, Cortesini R, Itescu S, Marboe C, Mancini D, Suciu-Foca N: Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation. Transpl Immunol. 2007 Jul;18(1):13-21. Epub 2007 Apr 2. [PubMed:17584597 ]
  5. Liu BY, Zhu P, Luo HB, Fu N: [Screening of short peptides binding to cell surface interleukin-2 receptor alpha chain]. Nan Fang Yi Ke Da Xue Xue Bao. 2006 Jul;26(7):971-4. [PubMed:16864089 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Ouyang Y, Kaminski NE: Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Arch Toxicol. 1999 Feb;73(1):1-6. [PubMed:10207608 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Interleukin-2 binding
Specific Function:
Common subunit for the receptors for a variety of interleukins.
Gene Name:
IL2RG
Uniprot ID:
P31785
Molecular Weight:
42286.68 Da
References
  1. Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA: Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2788-93. Epub 2006 Feb 13. [PubMed:16477002 ]
  2. Shibata F, Toma T, Wada T, Inoue M, Tone Y, Ohta K, Kasahara Y, Sano F, Kimura M, Ikeno M, Koizumi S, Yachie A: Skin infiltration of CD56(bright) CD16(-) natural killer cells in a case of X-SCID with Omenn syndrome-like manifestations. Eur J Haematol. 2007 Jul;79(1):81-5. [PubMed:17598841 ]
  3. Fonseca SG, Reis MM, Coelho V, Nogueira LG, Monteiro SM, Mairena EC, Bacal F, Bocchi E, Guilherme L, Zheng XX, Liew FY, Higuchi ML, Kalil J, Cunha-Neto E: Locally produced survival cytokines IL-15 and IL-7 may be associated to the predominance of CD8+ T cells at heart lesions of human chronic Chagas disease cardiomyopathy. Scand J Immunol. 2007 Aug-Sep;66(2-3):362-71. [PubMed:17635814 ]
  4. Blank RB, Lamb EW, Tocheva AS, Crow ET, Lim KC, McKerrow JH, Davies SJ: The common gamma chain cytokines interleukin (IL)-2 and IL-7 indirectly modulate blood fluke development via effects on CD4+ T cells. J Infect Dis. 2006 Dec 1;194(11):1609-16. Epub 2006 Oct 23. [PubMed:17083048 ]
  5. Smyth CM, Ginn SL, Deakin CT, Logan GJ, Alexander IE: Limiting {gamma}c expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors. Blood. 2007 Jul 1;110(1):91-8. Epub 2007 Mar 15. [PubMed:17363735 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Pyeon D, Diaz FJ, Splitter GA: Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus. J Virol. 2000 Jun;74(12):5740-5. [PubMed:10823885 ]
  2. Hamada T, Tsuchihashi S, Avanesyan A, Duarte S, Moore C, Busuttil RW, Coito AJ: Cyclooxygenase-2 deficiency enhances Th2 immune responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injury. J Immunol. 2008 Feb 1;180(3):1843-53. [PubMed:18209082 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Phospholipase a2 activity
Specific Function:
Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response.
Gene Name:
PLA2G4A
Uniprot ID:
P47712
Molecular Weight:
85238.2 Da
References
  1. Wolbink GJ, Schalkwijk C, Baars JW, Wagstaff J, van den Bosch H, Hack CE: Therapy with interleukin-2 induces the systemic release of phospholipase-A2. Cancer Immunol Immunother. 1995 Nov;41(5):287-92. [PubMed:8536274 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Elkahwaji J, Robin MA, Berson A, Tinel M, Letteron P, Labbe G, Beaune P, Elias D, Rougier P, Escudier B, Duvillard P, Pessayre D: Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol. 1999 Apr 15;57(8):951-4. [PubMed:10086330 ]
  2. Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD: Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos. 2004 Mar;32(3):359-63. [PubMed:14977871 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Xanthine oxidase activity
Specific Function:
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Has also low oxidase activity towards aldehydes (in vitro).
Gene Name:
XDH
Uniprot ID:
P47989
Molecular Weight:
146422.99 Da
References
  1. Faggioni R, Allavena P, Cantoni L, Carelli M, Demitri MT, Delgado R, Gatti S, Gnocchi P, Isetta AM, Paganin C, et al.: Mechanisms of interleukin-2-induced hydrothoraxy in mice: protective effect of endotoxin tolerance and dexamethasone and possible role of reactive oxygen intermediates. J Immunother Emphasis Tumor Immunol. 1994 Apr;15(3):194-201. [PubMed:8032542 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Elkahwaji J, Robin MA, Berson A, Tinel M, Letteron P, Labbe G, Beaune P, Elias D, Rougier P, Escudier B, Duvillard P, Pessayre D: Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol. 1999 Apr 15;57(8):951-4. [PubMed:10086330 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23